Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
memantine hydrochloride, Quantity: 10 mg
Arrotex Pharmaceuticals Pty Ltd
memantine hydrochloride
Tablet, film coated
Excipient Ingredients: macrogol 6000; hypromellose; microcrystalline cellulose; titanium dioxide; lactose monohydrate; magnesium stearate
Oral
56 tablets
(S4) Prescription Only Medicine
Treatment of the symptoms of moderately severe to severe Alzheimer's disease (see Pharmacodynamic properties and Special warnings and precautions for use).
Visual Identification: White to off-white, oval tablets, embossed with a scoreline on one side.; Container Type: Bottle; Container Material: HDPE; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius
Licence status A
2009-11-17
MEMANXA- Product Information Page 1 of 11 Memanxa PRODUCT INFORMATION NAME OF THE MEDICINE Memantine hydrochloride. The chemical name for memantine hydrochloride is 1-amino-3,5- dimethyl-adamantane hydrochloride. Its structural formula is: C 12 H 21 N.HCl Molecular weight: 215.77 Cas No.: 4110-52-1 DESCRIPTION Memantine hydrochloride is a colourless, crystalline substance with a bitter taste. The solubility of memantine hydrochloride in water at room temperature is about 3.5%. No polymorphic forms have been detected. Memanxa tablets contain 10 mg of memantine hydrochloride. The tablets also contain the following excipients: lactose, microcrystalline cellulose, magnesium stearate, hypromellose, macrogol 6000 and titanium dioxide. The tablets are gluten free. PHARMACOLOGY There is increasing evidence that malfunctioning of glutamatergic neurotransmission, in particular at (N-methyl-D -aspartate) NMDA receptors, contributes to both expression of symptoms and disease progression in neurodegenerative dementia. Memantine is a rapid, strongly voltage dependent, uncompetitive NMDA receptor antagonist. Prolonged increased levels of glutamate in the brain of demented patients are sufficient to counter the voltage dependent block of NMDA receptors by Mg 2+ ions and allow continuous influx of Ca 2+ ions into cells and ultimately neuronal degeneration. Studies suggest that memantine binds more effectively than Mg 2+ ions at the NMDA receptor, and thereby effectively blocks this prolonged influx of Ca 2+ ions through the NMDA channel while preserving the transient physiological activation of the channels by higher concentrations of synaptically released glutamate. Thus memantine protects against chronically elevated concentrations of glutamate. In animal models of disturbances in glutamatergic transmission memantine has been shown both to improve learning and to inhibit neurodegeneration at doses achieving plasma levels similar to those seen in clinical use. This in turn may explain the effect of memantine on dementia of the A Read the complete document